BindingDB Data by Journal
PMID
Data
Article Title
Citation
Organization
Download Data
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine.
Invest New Drugs 32: 825-37 (0)
Eli Lilly and Company